Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind announced the U.S. publication of its patent application covering a novel combination of MDMA and N-acylethanolamines (PEA) for treating PTSD, anxiety, and eating disorders. The IP advancement stems from the company's ongoing collaboration with NeuroThera Labs, expanding their joint portfolio to thirteen global patent applications.
Key figures
- Granted patents
- 32
- Collaboration patent applications
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.